Immunic says it’s on track to announce early data by year’s end from twin late-stage trials testing vidofludimus calcium (IMU-838) — an oral therapy believed to have both anti-inflammatory and neuroprotective properties — in people with relapsing forms of multiple sclerosis (MS). The top-line results from the…
vidofludimus calcium
Immunic Therapeutics has closed a private placement that could provide up to $400 million to support the company’s Phase 3 clinical program of vidofludimus calcium in multiple sclerosis (MS) and help fund its transition into a commercial-stage company as it prepares for potential regulatory approval of the…
Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium can target key mechanisms underlying disease progression in multiple sclerosis (MS), including acute and chronic inflammation, as well as Epstein-Barr virus (EBV) reactivation, according to new trial data. The Phase 2 CALLIPER trial (NCT05054140)Â investigated vidofludimus calcium against a…
Recommended Posts
- Blood levels of key protein may help predict MS progression
- Eye scans link retinal thinning to slower cognitive processing in MS
- In a life with multiple sclerosis, you have to know when ‘it is time’
- More antibody bands in spinal fluid tied to broader MRI lesions in MS
- Briumvi may outperform other MS therapies, indirect comparison shows